# Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

> **NCT03801915** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 10 (actual)

## Conditions studied

- Colon Cancer
- Pancreatic Cancer
- Cholangiocarcinoma
- Metastatic Colon Carcinoma
- Liver Metastasis

## Interventions

- **DRUG:** MVT-5873
- **PROCEDURE:** pancreatectomy or hepatectomy

## Key facts

- **NCT ID:** NCT03801915
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-13
- **Primary completion:** 2022-05-27
- **Final completion:** 2022-05-27
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2023-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03801915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03801915, "Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03801915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*